GlassScriptPhysician profile
Abby D Dickenson
NPI 1588174163
$1,801.98
in general payments reported to CMS, 2019-2025
10 companies · $1,359 in 2025
The $1,359 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.71 · 2022: $341 · 2024: $83.44 · 2025: $1,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,181 · Food and Beverage: $261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,181.32 |
| Food and Beverage | $260.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,242.01 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $183.42 | 2022-2024 | Opdivo |
| Regeneron Healthcare Solutions, INC. | $177.88 | 2022 | |
| Alexion Pharmaceuticals, INC. | $44.95 | 2022 | |
| Atricure, INC. | $44.43 | 2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Daiichi Sankyo INC. | $27.60 | 2025 | Enhertu |
| Genentech USA, INC. | $23.51 | 2025 | Tecentriq Hybreza, Tecentriq, Alecensa |
| On Target Laboratories, INC | $21.01 | 2025 | Cytalux |
| Coherus Oncology, INC. | $18.71 | 2021 | |
| Adc Therapeutics America, INC. | $18.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abby Dickenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.